Investigation into Valneva SE: A Call for Action for Affected Investors
New York, March 31, 2025 – Pomerantz LLP, a leading securities law firm, is currently investigating potential securities fraud claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN).
Background on Valneva SE
Valneva is a France-based biotech company specialized in developing and commercializing vaccines. Its portfolio includes vaccines for infectious diseases such as cholera, Lyme disease, and influenza. Valneva’s marketed products include Dukoral®, a vaccine against cholera, and Ixiaro®, a vaccine against Japanese encephalitis.
The Allegations
The investigation concerns certain allegations regarding Valneva’s business, financial condition, and/or its disclosures to the market and investors. Specifically, the firm is looking into the Company’s reported financial results, regulatory compliance, and internal controls. No further details are being disclosed at this time.
What This Means for Affected Investors
For investors who purchased or otherwise acquired Valneva securities between specific dates, they may be entitled to recover their losses. The investigation may lead to securities class action litigation. A securities class action is a lawsuit filed on behalf of a large group of investors who have suffered similar losses due to alleged violations of federal securities laws. The class action provides a cost-effective way for individual investors to pursue their claims.
How to Participate in the Investigation
If you are a Valneva investor and wish to discuss this investigation, you may, without obligation or cost to you, contact Danielle Peyton of Pomerantz LLP at [email protected] or 646-581-9980, ext. 167. You can also fill out the contact form on Pomerantz LLP’s website: www.pomlaw.com/contact-us
The Broader Implications
Beyond the specific allegations against Valneva, the investigation raises broader questions about the biotech sector and the regulatory environment. Biotech companies have seen significant growth in recent years, driven by advances in medical research and the increasing demand for innovative treatments. However, this growth has also led to increased scrutiny from regulators and investors, particularly in the areas of clinical trials, data transparency, and financial reporting.
The Impact on Valneva and the Biotech Sector
- Valneva’s stock price could experience volatility as a result of the investigation and any subsequent litigation.
- The investigation could lead to increased regulatory scrutiny of the biotech sector, potentially impacting other companies in the industry.
- Investors may become more cautious when investing in biotech companies, potentially leading to a slowdown in the sector’s growth.
Conclusion
The investigation into Valneva SE by Pomerantz LLP highlights the importance of transparency and accuracy in the disclosures made by publicly traded companies. It also underscores the risks associated with investing in the biotech sector, which can be volatile and subject to regulatory scrutiny. For affected investors, this investigation may lead to opportunities for recovery of their losses. For the broader market, it serves as a reminder of the importance of due diligence and staying informed about the companies in which they invest.
